A Phase 1/2A Single Center Trial of Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Using the Drug LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (LEAES)

Trial Profile

A Phase 1/2A Single Center Trial of Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Using the Drug LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (LEAES)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jan 2018

At a glance

  • Drugs EB 101 (Primary)
  • Indications Epidermolysis bullosa
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 18 Jan 2018 Status changed from recruiting to active, no longer recruiting.
    • 16 Jan 2018 The primary end point has been changed from Presence of type VII collagen to Percentage surface area of wound healing and Presence of anchoring fibrils to Investigator's assessment of graft.
    • 29 Aug 2017 Results published in an Abeona Therapeutics Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top